The company focuses in discovering and developing medicines that can offer therapeutic benefit to patients dealing with chronic or debilitating disease. Ms. Patterson began her career at KPMG working in the firm’s audit practice. Ms. Patterson has over 20 years of experience in the biotechnology industry. Adverum provides solutions to clients by implementing integrated and proactive communications strategies through strategic planning, public relations, media relations, crisis communications, … Earlier in her career, Ms. Patterson was vice president of finance at Exelixis, Inc. and vice president of global business planning and analysis at Novartis AG after the acquisition of Chiron.
Earlier, Ms. Patterson was vice president and chief financial officer of Transcept Pharmaceuticals, Inc. until it was acquired by Paratek Pharmaceuticals Inc. Adverum Biotechnologies, Inc. | 2,580 followers on LinkedIn | Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Previously, Ms. Patterson served as vice president and global corporate controller of NetApp, Inc. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. View Jean Chang’s professional profile on LinkedIn. Ms. Patterson is also a Certified Public Accountant (inactive status). Ms. Patterson currently serves on the board of directors for Nkarta, Inc. Since joining Adverum in 2016, she has served as chief financial officer, and most recently as president, chief executive officer and director. Adverum was formed after the merger of Avalanche Biotechnologies and Annapurna Therapeutics in May 2016. LinkedIn is the world's largest business network, helping professionals like Jean Chang discover inside connections to recommended job candidates, industry experts, and business partners. Adverum Biotechnologies, Inc. | LinkedIn‘de 2,575 takipçi | Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum | 496 Follower auf LinkedIn | Strategic Communications, PR and Media Relations, Digital Marketing, Creative and Graphic design. | Communications agency based in Vilnius, acting globally. Ms. Patterson has over 20 years of experience in the biotechnology industry. Previously, Ms. Patterson served as the chief financial officer of Diadexus, Inc. Leone Patterson is Adverum’s president, leading key operational functions for the Company. Adverum Biotechnologies, formerly Avalanche Biotechnologies, is a gene therapy company. Ms. Patterson earned a B.S. in Business Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary’s College. Since joining Adverum in 2016, she has served as chief financial officer, and most recently as president, chief executive officer and director. Leone Patterson is Adverum’s president, leading key operational functions for the Company.